FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
BP Equities (BP Wealth), Choice Equity Broking Pvt Ltd, Dilip Davda, Nirmal Bang and Reliance Securities have given "Apply" recommendation to Global Health IPO. Canara Bank, Capital Market, Jainam Broking limited and InvestorGain.com have given "May Apply" recommendation to Global Health IPO. Axis Capital, HDFC Securities Limited and Sharekhan Limited have "Not Rated" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 5 | 4 | 0 | 0 | 3 |
% | 41.67 | 33.33 | 0.00 | 0.00 | 25.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Axis Capital | Not Rated | |
BP Equities (BP Wealth) | Apply | |
Canara Bank | May Apply | |
Capital Market | May Apply | |
Choice Equity Broking Pvt Ltd | Apply | |
Dilip Davda | Apply | |
HDFC Securities Limited | Not Rated | |
Jainam Broking limited | May Apply | |
Nirmal Bang | Apply | |
Reliance Securities | Apply | |
Sharekhan Limited | Not Rated | |
InvestorGain.com | May Apply |
The Captial Market (CapitalMarket.com) rating for Global Health IPO is 45. Their analysis recommends May subscribe for the IPO.
Reviewer | Rating Score | Rating |
---|---|---|
Capital Market | 45 | May subscribe |
[Dilip Davda] GHL is operating under the most popular healthcare brand “Medanta” and posted growth over the years in its scale of operations. The issue is attractively priced based on its financial data and well compares with listed peers. Investors may consider an investment with medium to long-term perspectives. Read detail review...
Global Health IPO Reviews, analysis and views by popular members. Read Global Health Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 7 | 0 | 3 | 3 |
% | 53.85 | 0.00 | 23.08 | 23.08 |
Member | Review |
---|---|
XCapitalMarkets |
Apply for Long Term at Cut-off Price Great brand value, high-quality business, solid management. Growth path in place, and new hospitals ramping up fast. Valued at 18.5x FY22 EBITDA, whereas peers trade at average of 25x, so attractive pricing. November 3, 2022 9:29:36 AM |
Top Contributor |
Neutral May Apply November 1, 2022 9:26:35 AM |
Stark |
Avoid HUGE OFS ISSUE. NOT FAIRLY PRICED AND POST ISSUE HOLDING WILL JUST 33%. October 30, 2022 10:02:44 PM |
ramsita (300+ Posts) |
Avoid Uncertaintey November 3, 2022 1:51:14 PM |
Nomee |
Apply for Listing Gain at Upper Price Band This is THE Brand with reasonable valuation, Must subscribe. November 3, 2022 7:07:29 PM |
MAMU IPO Guru (2000+ Posts, 1200+ Likes) |
Neutral In waves of MAIN BOARD & SMES ipo, this will have a tough competition. |
Liger Top Contributor (300+ Posts, 500+ Likes) |
Neutral IPO pricing is at its fair value. |
Crow IPO Mentor (900+ Posts, 1100+ Likes) |
Apply for Listing Gain at Cut-off Price Barring poor GMP (12), high OFS (1700 cr), and low post-IPO promoter holding (33), I see some potential in this hospital stock. Hospitals have been usually well-received by the markets, plus the decent subscription levels tell me this may be a good bet even for longterm. Taking the gamble. 5 red flags out of 13. November 7, 2022 1:49:03 PM |
bansalVijay |
Apply for Listing Gain at Upper Price Band Many people are comparing it with max hospital and inferring Medanta costly but how. Max with 600 crores profit has market cap of 41000 crores while Medanta with 200 crores profit seems to have market cap of 8000 crores. Can anyone shed light on this. October 30, 2022 10:39:44 AM |
B.M.SURANA IPO Guru (2700+ Posts, 5300+ Likes) |
Apply for Long Term at Cut-off Price Fundamentally strong Company. |
arunARUN IPO Guru (2000+ Posts, 1700+ Likes) |
Apply for Short Term at Cut-off Price Attractively priced. Though share is good for long term also but in short term prices may run ahead of fundamentals October 29, 2022 9:05:21 AM |
AJS |
Apply for Long Term at Upper Price Band Available at reasonable valuations compared to Apollo, Fortis. November 2, 2022 9:31:15 PM |
Abhijeet Kumar |
Avoid Instead of applying in such poor quality IPO like Fusion and Global health its better to buy good quality scrips from secondary market which are trading at cheap valuations. Few of my suggestions to buy would be : Sanofi India, Johnson Control, Tamilnad Merchantile Bank, GE T&D India, Bector Foods, Railtel etc, November 3, 2022 2:20:31 AM |
Post Recommendation Manage Recommendations
Note:
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|